Core Insights - The strategic partnership between Yuejiang and Yaoshibang focuses on pharmaceutical collaborative robots, AI models, and drug IoT technology [1] - Both companies aim to explore smart solutions across the pharmaceutical supply chain, including research, warehousing, distribution, retail, and medication services [1] - The collaboration is expected to enhance the integration of robotics technology within the pharmaceutical industry, aligning with their respective missions [1] Company Collaboration - Yuejiang and Yaoshibang have signed a strategic cooperation agreement effective June 3, 2025, initiating a close partnership and specific project deployments [1] - Yaoshibang will handle the research and validation of application scenarios, while Yuejiang will focus on technology development, product production, and after-sales maintenance [1] Initial Project Phase - The first phase of the collaboration will target the pharmacy and drug warehouse collaborative robot sector [2] - The companies have identified their first project, completing feasibility studies, technical route assessments, and environment selection, and have begun building a testing platform [2]

Core Viewpoint - Two Hong Kong companies, Yuejiang (02432.HK) and Yaoshibang (09885.HK), have signed a strategic cooperation agreement to explore the application of intelligent robotics and AI in the pharmaceutical industry, aiming to enhance efficiency and innovation across the entire supply chain [1][2]. Group 1: Strategic Cooperation - The partnership will focus on the development and deployment of intelligent robots in pharmacies and drug warehouses, with both companies sharing technology and intellectual property generated during the collaboration [2]. - Yuejiang will handle technology development, production, and maintenance of the robots, while Yaoshibang will focus on application research and sales [1][2]. Group 2: Market Potential - According to a report by ZhiShi Industry Consulting, the global collaborative robot market in the healthcare sector is expected to reach $373 million by 2028, indicating significant growth potential [3]. - Yuejiang anticipates that the pharmaceutical sector will become a key area for the application and promotion of collaborative robots [3]. Group 3: Company Performance - On June 3, Yuejiang's stock rose by 0.87%, with a market capitalization exceeding HKD 20 billion, reflecting a year-to-date increase of 144.30% [3]. - Yaoshibang's stock increased by 4.79% on the same day, with a market capitalization of approximately HKD 6.9 billion and a year-to-date rise of 78.37% [3].

Group 1 - The core viewpoint of the news is that 越疆 (02432) has entered into a strategic cooperation agreement with 药师帮股份有限公司 (09885) to explore the integration of robotics and AI in the pharmaceutical industry [1][2] - The collaboration will focus on pharmaceutical collaborative robots, AI large models, and drug IoT technology, aiming to enhance applications in drug research, storage, distribution, retail, and medication services [1] - The first phase of the cooperation will target the deployment of collaborative robots in pharmacies and drug warehouses, with a feasibility study and technical assessments already completed [1] Group 2 - Both parties will adhere to principles of collaborative innovation and mutual development, sharing technical data and newly generated intellectual property and trade secrets [2] - The agreement grants the group exclusive production rights for the robots, while 药师帮 will have exclusive sales rights in the pharmaceutical sector [2] - The board of the group believes that this strategic partnership will facilitate resource integration, collaborative innovation, and promote technological advancement in the industry, ultimately benefiting social health [2]